CN114728093B - 止血及伤口治愈用创伤敷料及其制备方法 - Google Patents
止血及伤口治愈用创伤敷料及其制备方法 Download PDFInfo
- Publication number
- CN114728093B CN114728093B CN202080080438.9A CN202080080438A CN114728093B CN 114728093 B CN114728093 B CN 114728093B CN 202080080438 A CN202080080438 A CN 202080080438A CN 114728093 B CN114728093 B CN 114728093B
- Authority
- CN
- China
- Prior art keywords
- wound dressing
- minutes
- sodium
- freeze
- wound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010052428 Wound Diseases 0.000 title abstract description 81
- 208000027418 Wounds and injury Diseases 0.000 title abstract description 81
- 238000002360 preparation method Methods 0.000 title abstract description 11
- 230000029663 wound healing Effects 0.000 title abstract description 10
- 230000023597 hemostasis Effects 0.000 title abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 34
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 25
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 24
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 24
- 238000004108 freeze drying Methods 0.000 claims abstract description 22
- 108010035532 Collagen Proteins 0.000 claims abstract description 21
- 102000008186 Collagen Human genes 0.000 claims abstract description 21
- 229920001436 collagen Polymers 0.000 claims abstract description 21
- 238000002156 mixing Methods 0.000 claims abstract description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- 239000007864 aqueous solution Substances 0.000 claims description 13
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 7
- 230000002745 absorbent Effects 0.000 claims description 6
- 239000002250 absorbent Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000010998 test method Methods 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 238000007906 compression Methods 0.000 claims description 3
- 230000006835 compression Effects 0.000 claims description 3
- 238000010894 electron beam technology Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 241000251468 Actinopterygii Species 0.000 claims description 2
- 241000283690 Bos taurus Species 0.000 claims description 2
- 241001494479 Pecora Species 0.000 claims description 2
- 241000282887 Suidae Species 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 238000004388 gamma ray sterilization Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 230000001737 promoting effect Effects 0.000 abstract description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 14
- 239000011734 sodium Substances 0.000 description 14
- 229910052708 sodium Inorganic materials 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 10
- 230000002439 hemostatic effect Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 229940014041 hyaluronate Drugs 0.000 description 9
- 239000013642 negative control Substances 0.000 description 9
- 230000000740 bleeding effect Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 5
- 229930195573 Amycin Natural products 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- SVSFIELZISOJDT-XRZFDKQNSA-N (6r,7r)-7-[[2-(2-amino-1,3-thiazol-4-yl)acetyl]amino]-3-[[1-[2-(dimethylamino)ethyl]tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrochloride Chemical compound Cl.CN(C)CCN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC=3N=C(N)SC=3)[C@H]2SC1 SVSFIELZISOJDT-XRZFDKQNSA-N 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000015271 coagulation Effects 0.000 description 4
- 238000005345 coagulation Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- OKJPEAGHQZHRQV-UHFFFAOYSA-N iodoform Chemical compound IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 4
- IPYWNMVPZOAFOQ-NABDTECSSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;trihydrate Chemical compound O.O.O.S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 IPYWNMVPZOAFOQ-NABDTECSSA-N 0.000 description 3
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 3
- YWMSSKBMOFPBDM-UHFFFAOYSA-N 4-carbamoylbenzenesulfonyl chloride Chemical compound NC(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 YWMSSKBMOFPBDM-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 108010001478 Bacitracin Proteins 0.000 description 3
- 206010063560 Excessive granulation tissue Diseases 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 description 3
- 238000010162 Tukey test Methods 0.000 description 3
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 3
- 229960001656 amikacin sulfate Drugs 0.000 description 3
- 229960003071 bacitracin Drugs 0.000 description 3
- 229930184125 bacitracin Natural products 0.000 description 3
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 229960002129 cefixime Drugs 0.000 description 3
- 229960004700 cefotiam hydrochloride Drugs 0.000 description 3
- 229960002588 cefradine Drugs 0.000 description 3
- 229960000636 ceftizoxime sodium Drugs 0.000 description 3
- ADLFUPFRVXCDMO-LIGXYSTNSA-M ceftizoxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=CCS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 ADLFUPFRVXCDMO-LIGXYSTNSA-M 0.000 description 3
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229960003276 erythromycin Drugs 0.000 description 3
- 210000001126 granulation tissue Anatomy 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- -1 ribosyl sulfate Chemical compound 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 229940010747 sodium hyaluronate Drugs 0.000 description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 3
- BWRBVBFLFQKBPT-UHFFFAOYSA-N (2-nitrophenyl)methanol Chemical compound OCC1=CC=CC=C1[N+]([O-])=O BWRBVBFLFQKBPT-UHFFFAOYSA-N 0.000 description 2
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 2
- WTJXVDPDEQKTCV-UHFFFAOYSA-N 4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2C1CC1C(N(C)C)C(=O)C(C(N)=O)=C(O)C1(O)C2=O WTJXVDPDEQKTCV-UHFFFAOYSA-N 0.000 description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 2
- IYLLULUTZPKQBW-UHFFFAOYSA-N Acrinol Chemical compound CC(O)C(O)=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 IYLLULUTZPKQBW-UHFFFAOYSA-N 0.000 description 2
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 2
- BHELIUBJHYAEDK-OAIUPTLZSA-N Aspoxicillin Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3[C@H](C(C)(C)S[C@@H]32)C(O)=O)=O)NC(=O)[C@H](N)CC(=O)NC)=CC=C(O)C=C1 BHELIUBJHYAEDK-OAIUPTLZSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- WNJOIIXGSLBJAS-FDVIUCIPSA-M Cefbuperazone sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H]([C@H](C)O)C(=O)N[C@]1(OC)C(=O)N2C(C([O-])=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 WNJOIIXGSLBJAS-FDVIUCIPSA-M 0.000 description 2
- NCFTXMQPRQZFMZ-WERGMSTESA-M Cefoperazone sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C([O-])=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 NCFTXMQPRQZFMZ-WERGMSTESA-M 0.000 description 2
- REACMANCWHKJSM-DWBVFMGKSA-M Cefsulodin sodium Chemical compound [Na+].C1=CC(C(=O)N)=CC=[N+]1CC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)[C@@H](C=3C=CC=CC=3)S([O-])(=O)=O)[C@H]2SC1 REACMANCWHKJSM-DWBVFMGKSA-M 0.000 description 2
- KEJCWVGMRLCZQQ-YJBYXUATSA-N Cefuroxime axetil Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(=O)OC(C)OC(C)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 KEJCWVGMRLCZQQ-YJBYXUATSA-N 0.000 description 2
- URDOHUPGIOGTKV-JTBFTWTJSA-M Cefuroxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 URDOHUPGIOGTKV-JTBFTWTJSA-M 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- LIRCDOVJWUGTMW-ZWNOBZJWSA-N Chloramphenicol succinate Chemical compound OC(=O)CCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 LIRCDOVJWUGTMW-ZWNOBZJWSA-N 0.000 description 2
- 108010078777 Colistin Proteins 0.000 description 2
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 2
- KGWDUNBJIMUFAP-KVVVOXFISA-N Ethanolamine Oleate Chemical compound NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O KGWDUNBJIMUFAP-KVVVOXFISA-N 0.000 description 2
- OVMMHVNNFBJRNE-CACIRBSMSA-M Flomoxef sodium Chemical compound [Na+].O([C@@H]1[C@@](C(N1C=1C([O-])=O)=O)(CC(=O)CSC(F)F)OC)CC=1CSC1=NN=NN1CCO OVMMHVNNFBJRNE-CACIRBSMSA-M 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- RKTNPKZEPLCLSF-GNERTXCBSA-N OS([O-])(=O)=O.N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 Chemical compound OS([O-])(=O)=O.N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 RKTNPKZEPLCLSF-GNERTXCBSA-N 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 229920000153 Povidone-iodine Polymers 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 229960002684 aminocaproic acid Drugs 0.000 description 2
- 229960003022 amoxicillin Drugs 0.000 description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960001931 ampicillin sodium Drugs 0.000 description 2
- KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940030225 antihemorrhagics Drugs 0.000 description 2
- 229960000202 aspoxicillin Drugs 0.000 description 2
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 2
- 229960003644 aztreonam Drugs 0.000 description 2
- YGTPKDKJVZOVCO-KELBJJLKSA-N bekanamycin sulfate Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N YGTPKDKJVZOVCO-KELBJJLKSA-N 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- 229960001950 benzethonium chloride Drugs 0.000 description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- CZPLANDPABRVHX-UHFFFAOYSA-N cascade blue Chemical compound C=1C2=CC=CC=C2C(NCC)=CC=1C(C=1C=CC(=CC=1)N(CC)CC)=C1C=CC(=[N+](CC)CC)C=C1 CZPLANDPABRVHX-UHFFFAOYSA-N 0.000 description 2
- 210000004534 cecum Anatomy 0.000 description 2
- 229960005361 cefaclor Drugs 0.000 description 2
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 2
- 229960004841 cefadroxil Drugs 0.000 description 2
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 2
- OJMNTWPPFNMOCJ-CFOLLTDRSA-M cefamandole sodium Chemical compound [Na+].CN1N=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OJMNTWPPFNMOCJ-CFOLLTDRSA-M 0.000 description 2
- 229960003408 cefazolin sodium Drugs 0.000 description 2
- FLKYBGKDCCEQQM-WYUVZMMLSA-M cefazolin sodium Chemical compound [Na+].S1C(C)=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 FLKYBGKDCCEQQM-WYUVZMMLSA-M 0.000 description 2
- 229960003719 cefdinir Drugs 0.000 description 2
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 description 2
- 229960002142 cefditoren pivoxil Drugs 0.000 description 2
- AFZFFLVORLEPPO-UVYJNCLZSA-N cefditoren pivoxil Chemical compound S([C@@H]1[C@@H](C(N1C=1C(=O)OCOC(=O)C(C)(C)C)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1\C=C/C=1SC=NC=1C AFZFFLVORLEPPO-UVYJNCLZSA-N 0.000 description 2
- LRAJHPGSGBRUJN-OMIVUECESA-N cefepime hydrochloride Chemical compound O.Cl.[Cl-].S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 LRAJHPGSGBRUJN-OMIVUECESA-N 0.000 description 2
- 229960000927 cefepime hydrochloride Drugs 0.000 description 2
- 229960003791 cefmenoxime Drugs 0.000 description 2
- MPTNDTIREFCQLK-UNVJPQNDSA-N cefmenoxime hydrochloride Chemical compound [H+].[Cl-].S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NN=NN1C.S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NN=NN1C MPTNDTIREFCQLK-UNVJPQNDSA-N 0.000 description 2
- SNBUBQHDYVFSQF-HIFRSBDPSA-N cefmetazole Chemical compound S([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSCC#N)OC)CC=1CSC1=NN=NN1C SNBUBQHDYVFSQF-HIFRSBDPSA-N 0.000 description 2
- 229960002676 cefmetazole sodium Drugs 0.000 description 2
- SBIDXLKJYJVQOE-YNJMIPHHSA-M cefminox sodium Chemical compound [Na+].S([C@@H]1[C@@](C(N1C=1C([O-])=O)=O)(NC(=O)CSC[C@@H](N)C(O)=O)OC)CC=1CSC1=NN=NN1C SBIDXLKJYJVQOE-YNJMIPHHSA-M 0.000 description 2
- 229960002417 cefoperazone sodium Drugs 0.000 description 2
- 229960005446 cefpiramide Drugs 0.000 description 2
- RIWWMGQFMUUYIY-ALLHVENQSA-M cefpiramide sodium Chemical compound [Na+].C1=NC(C)=CC(O)=C1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C([O-])=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 RIWWMGQFMUUYIY-ALLHVENQSA-M 0.000 description 2
- 229960002838 cefpirome sulfate Drugs 0.000 description 2
- LTINZAODLRIQIX-FBXRGJNPSA-N cefpodoxime proxetil Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(=O)OC(C)OC(=O)OC(C)C)C(=O)C(=N/OC)\C1=CSC(N)=N1 LTINZAODLRIQIX-FBXRGJNPSA-N 0.000 description 2
- 229960004797 cefpodoxime proxetil Drugs 0.000 description 2
- 229960000484 ceftazidime Drugs 0.000 description 2
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 2
- 229960002940 ceftazidime sodium Drugs 0.000 description 2
- JEEWDSDYUSEQML-ROMZVAKDSA-M ceftazidime sodium Chemical compound [Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C([O-])=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 JEEWDSDYUSEQML-ROMZVAKDSA-M 0.000 description 2
- 229960000479 ceftriaxone sodium Drugs 0.000 description 2
- 229960002620 cefuroxime axetil Drugs 0.000 description 2
- 229960000534 cefuroxime sodium Drugs 0.000 description 2
- 229940106164 cephalexin Drugs 0.000 description 2
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 2
- 229960001805 chloramphenicol palmitate Drugs 0.000 description 2
- PXKHGMGELZGJQE-ILBGXUMGSA-N chloramphenicol palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 PXKHGMGELZGJQE-ILBGXUMGSA-N 0.000 description 2
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 2
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 229960001127 colistin sulfate Drugs 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- FWRNIJIOFYDBES-ZQDFAFASSA-L disodium;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[[(2r)-2-phenyl-2-sulfonatoacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate Chemical compound [Na+].[Na+].C1([C@H](C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)S([O-])(=O)=O)=CC=CC=C1 FWRNIJIOFYDBES-ZQDFAFASSA-L 0.000 description 2
- MOGICMVNWAUWMK-HIXRZVNASA-L disodium;(5r,6s)-6-[(1r)-1-hydroxyethyl]-7-oxo-3-[(2r)-oxolan-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate;pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].S([C@@H]1[C@H](C(N1C=1C([O-])=O)=O)[C@H](O)C)C=1[C@H]1CCCO1.S([C@@H]1[C@H](C(N1C=1C([O-])=O)=O)[C@H](O)C)C=1[C@H]1CCCO1 MOGICMVNWAUWMK-HIXRZVNASA-L 0.000 description 2
- FDRNWTJTHBSPMW-GNXCPKRQSA-L disodium;(6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-6-oxido-5-oxo-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].[Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C([O-])=NN1C FDRNWTJTHBSPMW-GNXCPKRQSA-L 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000000556 factor analysis Methods 0.000 description 2
- 229960000379 faropenem Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960000308 fosfomycin Drugs 0.000 description 2
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 2
- 230000005251 gamma ray Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000002874 hemostatic agent Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 2
- 229960002064 kanamycin sulfate Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229960002421 minocycline hydrochloride Drugs 0.000 description 2
- 229960005068 monoethanolamine oleate Drugs 0.000 description 2
- 229960004715 morphine sulfate Drugs 0.000 description 2
- GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 2
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 2
- ZESIAEVDVPWEKB-ORCFLVBFSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O ZESIAEVDVPWEKB-ORCFLVBFSA-N 0.000 description 2
- 229960004832 netilmicin sulfate Drugs 0.000 description 2
- 229960004368 oxytetracycline hydrochloride Drugs 0.000 description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 235000019371 penicillin G benzathine Nutrition 0.000 description 2
- NONJJLVGHLVQQM-JHXYUMNGSA-N phenethicillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(C)OC1=CC=CC=C1 NONJJLVGHLVQQM-JHXYUMNGSA-N 0.000 description 2
- 229960004894 pheneticillin Drugs 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 229960005264 piperacillin sodium Drugs 0.000 description 2
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229960001621 povidone-iodine Drugs 0.000 description 2
- 230000003405 preventing effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 2
- 229960001225 rifampicin Drugs 0.000 description 2
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 2
- 229960001435 sisomicin sulfate Drugs 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 2
- 229960000887 spectinomycin hydrochloride Drugs 0.000 description 2
- ZPCCSZFPOXBNDL-RSMXASMKSA-N spiramycin II Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]([C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)OC(C)=O)[C@H]1CC[C@H](N(C)C)[C@H](C)O1 ZPCCSZFPOXBNDL-RSMXASMKSA-N 0.000 description 2
- 229950006796 spiramycin ii Drugs 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960002385 streptomycin sulfate Drugs 0.000 description 2
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 2
- 229960004306 sulfadiazine Drugs 0.000 description 2
- 229960002135 sulfadimidine Drugs 0.000 description 2
- ASWVTGNCAZCNNR-UHFFFAOYSA-N sulfamethazine Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ASWVTGNCAZCNNR-UHFFFAOYSA-N 0.000 description 2
- 229960005404 sulfamethoxazole Drugs 0.000 description 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
- 229960001940 sulfasalazine Drugs 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 229960000707 tobramycin Drugs 0.000 description 2
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 2
- MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 2
- LCTORFDMHNKUSG-XTTLPDOESA-N vancomycin monohydrochloride Chemical compound Cl.O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 LCTORFDMHNKUSG-XTTLPDOESA-N 0.000 description 2
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
- KGKMNZPJZKQEIF-DVKMMUIASA-N (2S,3S,4S,5R)-2,3,4,5-tetrahydroxy-6-oxohexanoic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(=O)O.O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(=O)O KGKMNZPJZKQEIF-DVKMMUIASA-N 0.000 description 1
- DRLJIPQOBJCEET-YWUHCJSESA-N (2s,5r,6r)-6-[[(2r)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrochloride Chemical compound Cl.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 DRLJIPQOBJCEET-YWUHCJSESA-N 0.000 description 1
- DZKQVWCTFCSEKF-QOEBQMAPSA-N (3r,4r)-3,6-diamino-n-[(3s,6z,9s,12s,15s)-3-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-6-[(carbamoylamino)methylidene]-9,12-bis(hydroxymethyl)-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentazacyclohexadec-15-yl]-4-hydroxyhexanamide;sulfuric acid Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.N1C(=O)\C(=C\NC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)C[C@@H](N)[C@H](O)CCN)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C\NC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)C[C@@H](N)[C@H](O)CCN)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 DZKQVWCTFCSEKF-QOEBQMAPSA-N 0.000 description 1
- WTJXVDPDEQKTCV-VQAITOIOSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O WTJXVDPDEQKTCV-VQAITOIOSA-N 0.000 description 1
- OAPVUSSHCBRCOL-KBHRXELFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O OAPVUSSHCBRCOL-KBHRXELFSA-N 0.000 description 1
- CKOIKOHDEYTLFR-PFBPGKLMSA-N (6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)-1-oxoethyl]amino]-8-oxo-3-[(2H-triazol-4-ylthio)methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid propane-1,2-diol Chemical compound CC(O)CO.S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](N)C=2C=CC(O)=CC=2)CC=1CSC=1C=NNN=1 CKOIKOHDEYTLFR-PFBPGKLMSA-N 0.000 description 1
- NTJHUKMPVIFDNY-XFDPNJHTSA-N (6r,7r)-7-[[(2z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-methoxyiminoacetyl]amino]-3-(imidazo[1,2-b]pyridazin-4-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;chloride Chemical compound [Cl-].N([C@@H]1C(N2C(=C(CN3C4=CC=CN=[N+]4C=C3)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=NSC(N)=N1 NTJHUKMPVIFDNY-XFDPNJHTSA-N 0.000 description 1
- KCUAVDXLFXNGDG-MZFDKZDRSA-N 15207-30-4 Chemical compound Cl.Cl.C([C@@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(N[C@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(C)C)C(=O)N1)C(C)C)=O)CC(C)C)C(C)C)C1=CC=CC=C1 KCUAVDXLFXNGDG-MZFDKZDRSA-N 0.000 description 1
- LUXIJPQYUCFVAL-XRLCNELCSA-N 2,2-dimethylpropanoyloxymethyl (6r,7r)-7-[[(z)-2-(2-amino-1,3-thiazol-4-yl)pent-2-enoyl]amino]-3-(carbamoyloxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate;hydron;chloride;hydrate Chemical compound O.Cl.N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(=O)OCOC(=O)C(C)(C)C)=O)C(=O)\C(=C/CC)C1=CSC(N)=N1 LUXIJPQYUCFVAL-XRLCNELCSA-N 0.000 description 1
- SZIFAVKTNFCBPC-UHFFFAOYSA-N 2-chloroethanol Chemical compound OCCCl SZIFAVKTNFCBPC-UHFFFAOYSA-N 0.000 description 1
- FZIPCQLKPTZZIM-UHFFFAOYSA-N 2-oxidanylpropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FZIPCQLKPTZZIM-UHFFFAOYSA-N 0.000 description 1
- PTNZGHXUZDHMIQ-UHFFFAOYSA-N 4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2C(C)C(C(O)C3C(C(O)=C(C(N)=O)C(=O)C3N(C)C)(O)C3=O)C3=C(O)C2=C1O PTNZGHXUZDHMIQ-UHFFFAOYSA-N 0.000 description 1
- RPABDKTXMKOGKI-OYTUFZPASA-N 6-methyl-n-[2-[(2s,5s,8s,11s,14s,17s,20s,23s)-8,11,14,20-tetrakis(2-aminoethyl)-5-[(1r)-1-hydroxyethyl]-17,23-bis(2-methylpropyl)-3,6,9,12,15,18,21,24-octaoxo-1,4,7,10,13,16,19,22-octazacyclotetracos-2-yl]ethyl]octanamide Chemical compound CCC(C)CCCCC(=O)NCC[C@@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H]([C@@H](C)O)NC1=O RPABDKTXMKOGKI-OYTUFZPASA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UIYAXIPXULMHAI-JLGRZTKVSA-N Cefteram pivoxil Chemical compound S([C@@H]1[C@@H](C(N1C=1C(=O)OCOC(=O)C(C)(C)C)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CN1N=NC(C)=N1 UIYAXIPXULMHAI-JLGRZTKVSA-N 0.000 description 1
- UGUMHWUOXWFPFH-JHQAJZDGSA-M Ceftezole Sodium Chemical compound [Na+].O=C([C@@H](NC(=O)CN1N=NN=C1)[C@H]1SC2)N1C(C(=O)[O-])=C2CSC1=NN=CS1 UGUMHWUOXWFPFH-JHQAJZDGSA-M 0.000 description 1
- 241000561734 Celosia cristata Species 0.000 description 1
- 108010073254 Colicins Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- IEMDOFXTVAPVLX-YWQHLDGFSA-N Leucomycin A1 Chemical compound CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@@H](C)O1 IEMDOFXTVAPVLX-YWQHLDGFSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 description 1
- WSSMMNVKLQZMEF-BEKOLJTOSA-N N-[(3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O.CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O WSSMMNVKLQZMEF-BEKOLJTOSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 108010053950 Teicoplanin Proteins 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- FXXSETTYJSGMCR-GLCLSGQWSA-N Valacillin (TN) Chemical compound [Cl-].O1C(=O)OC(COC(=O)[C@H]2C(S[C@H]3[NH+]2C([C@H]3NC(=O)[C@H](N)C=2C=CC=CC=2)=O)(C)C)=C1C FXXSETTYJSGMCR-GLCLSGQWSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- MKKYBZZTJQGVCD-XTCKQBCOSA-N arbekacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)CC[C@H]1N MKKYBZZTJQGVCD-XTCKQBCOSA-N 0.000 description 1
- 229940087147 arbekacin sulfate Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229950004074 astromicin Drugs 0.000 description 1
- BIDUPMYXGFNAEJ-APGVDKLISA-N astromicin Chemical compound O[C@@H]1[C@H](N(C)C(=O)CN)[C@@H](OC)[C@@H](O)[C@H](N)[C@H]1O[C@@H]1[C@H](N)CC[C@@H]([C@H](C)N)O1 BIDUPMYXGFNAEJ-APGVDKLISA-N 0.000 description 1
- 108010045569 atelocollagen Proteins 0.000 description 1
- 229960005412 bacampicillin hydrochloride Drugs 0.000 description 1
- IWVTXAGTHUECPN-ANBBSHPLSA-N bacampicillin hydrochloride Chemical compound [H+].[Cl-].C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OC(C)OC(=O)OCC)=CC=CC=C1 IWVTXAGTHUECPN-ANBBSHPLSA-N 0.000 description 1
- 229960002536 benzathine benzylpenicillin Drugs 0.000 description 1
- BVGLIYRKPOITBQ-ANPZCEIESA-N benzylpenicillin benzathine Chemical compound C=1C=CC=CC=1C[NH2+]CC[NH2+]CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 BVGLIYRKPOITBQ-ANPZCEIESA-N 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960004353 carbazochrome sodium sulfonate Drugs 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- BGGXRVPCJUKHTQ-AHCAJXDVSA-L carumonam sodium Chemical compound [Na+].[Na+].O=C1N(S([O-])(=O)=O)[C@H](COC(=O)N)[C@@H]1NC(=O)C(=N/OCC([O-])=O)\C1=CSC(N)=N1 BGGXRVPCJUKHTQ-AHCAJXDVSA-L 0.000 description 1
- 229960003866 cefaloridine Drugs 0.000 description 1
- CZTQZXZIADLWOZ-CRAIPNDOSA-N cefaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960002966 cefcapene Drugs 0.000 description 1
- HJJRIJDTIPFROI-NVKITGPLSA-N cefcapene Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=C/CC)C1=CSC(N)=N1 HJJRIJDTIPFROI-NVKITGPLSA-N 0.000 description 1
- 229950004627 cefcapene pivoxil Drugs 0.000 description 1
- MQLRYUCJDNBWMV-GHXIOONMSA-N cefetamet Chemical compound N([C@@H]1C(N2C(=C(C)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 MQLRYUCJDNBWMV-GHXIOONMSA-N 0.000 description 1
- 229950000726 cefetamet pivoxil Drugs 0.000 description 1
- DASYMCLQENWCJG-XUKDPADISA-N cefetamet pivoxil Chemical compound N([C@@H]1C(N2C(=C(C)CS[C@@H]21)C(=O)OCOC(=O)C(C)(C)C)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 DASYMCLQENWCJG-XUKDPADISA-N 0.000 description 1
- 229950001580 cefoselis Drugs 0.000 description 1
- LZOLCSVRFKCSEM-ZQCAECPKSA-N cefoselis sulfate Chemical compound OS(O)(=O)=O.S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CN1C=CC(=N)N1CCO LZOLCSVRFKCSEM-ZQCAECPKSA-N 0.000 description 1
- 229960002727 cefotaxime sodium Drugs 0.000 description 1
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 1
- ZQQALMSFFARWPK-ZTQQJVKJSA-L cefotetan disodium Chemical compound [Na+].[Na+].N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C([O-])=O)=O)C(=O)C1SC(=C(C(N)=O)C([O-])=O)S1 ZQQALMSFFARWPK-ZTQQJVKJSA-L 0.000 description 1
- 229950010227 cefotiam hexetil Drugs 0.000 description 1
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 description 1
- 229960003844 cefroxadine Drugs 0.000 description 1
- RDMOROXKXONCAL-UEKVPHQBSA-N cefroxadine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)OC)C(O)=O)=CCC=CC1 RDMOROXKXONCAL-UEKVPHQBSA-N 0.000 description 1
- 229960001281 cefsulodin sodium Drugs 0.000 description 1
- 229950002506 cefteram pivoxil Drugs 0.000 description 1
- 229960004366 ceftezole Drugs 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 230000004956 cell adhesive effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 1
- 229940009063 cephapirin sodium Drugs 0.000 description 1
- VGEOUKPOQQEQSX-OALZAMAHSA-M cephapirin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CSC1=CC=NC=C1 VGEOUKPOQQEQSX-OALZAMAHSA-M 0.000 description 1
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960002579 chloramphenicol sodium succinate Drugs 0.000 description 1
- 229960004357 chloramphenicol succinate Drugs 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- 229960001200 clindamycin hydrochloride Drugs 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 108700028201 colistinmethanesulfonic acid Proteins 0.000 description 1
- 210000001520 comb Anatomy 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229960003077 cycloserine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- JJCQSGDBDPYCEO-XVZSLQNASA-N dibekacin Chemical compound O1[C@H](CN)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N JJCQSGDBDPYCEO-XVZSLQNASA-N 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 229960001172 doxycycline hyclate Drugs 0.000 description 1
- HALQELOKLVRWRI-VDBOFHIQSA-N doxycycline hyclate Chemical compound O.[Cl-].[Cl-].CCO.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O HALQELOKLVRWRI-VDBOFHIQSA-N 0.000 description 1
- 229960004082 doxycycline hydrochloride Drugs 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 229950000219 enviomycin Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229960003203 erythromycin estolate Drugs 0.000 description 1
- AWMFUEJKWXESNL-JZBHMOKNSA-N erythromycin estolate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(=O)CC)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AWMFUEJKWXESNL-JZBHMOKNSA-N 0.000 description 1
- 229960000741 erythromycin ethylsuccinate Drugs 0.000 description 1
- NSYZCCDSJNWWJL-YXOIYICCSA-N erythromycin ethylsuccinate Chemical compound O1[C@H](C)C[C@H](N(C)C)[C@@H](OC(=O)CCC(=O)OCC)[C@@H]1O[C@H]1[C@@](O)(C)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(OC)C2)[C@@H]1C NSYZCCDSJNWWJL-YXOIYICCSA-N 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 229960004675 fusidic acid Drugs 0.000 description 1
- POUMFISTNHIPTI-BOMBIWCESA-N hydron;(2s,4r)-n-[(1r,2r)-2-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide;chloride Chemical compound Cl.CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 POUMFISTNHIPTI-BOMBIWCESA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- VJVOFLWZDWLHNR-MRCUWXFGSA-N icosan-9-yl (z)-docos-13-enoate Chemical compound CCCCCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCCCCC\C=C/CCCCCCCC VJVOFLWZDWLHNR-MRCUWXFGSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229960000798 isepamicin Drugs 0.000 description 1
- UDIIBEDMEYAVNG-ZKFPOVNWSA-N isepamicin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)O)[C@@H](N)C[C@H]1NC(=O)[C@@H](O)CN UDIIBEDMEYAVNG-ZKFPOVNWSA-N 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 229950005831 lenampicillin Drugs 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960001595 lincomycin hydrochloride Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- CTUAQTBUVLKNDJ-OBZXMJSBSA-N meropenem trihydrate Chemical compound O.O.O.C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 CTUAQTBUVLKNDJ-OBZXMJSBSA-N 0.000 description 1
- 229960003106 micronomicin sulfate Drugs 0.000 description 1
- MQDGQSCLOYLSEK-SCFBDNQUSA-N micronomicin sulfate Chemical compound OS(O)(=O)=O.O1[C@H](CNC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N MQDGQSCLOYLSEK-SCFBDNQUSA-N 0.000 description 1
- 229960005195 morphine hydrochloride Drugs 0.000 description 1
- XELXKCKNPPSFNN-BJWPBXOKSA-N morphine hydrochloride trihydrate Chemical compound O.O.O.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XELXKCKNPPSFNN-BJWPBXOKSA-N 0.000 description 1
- 229960000313 mupirocin calcium Drugs 0.000 description 1
- WIDKTXGNSOORHA-CJHXQPGBSA-N n,n'-dibenzylethane-1,2-diamine;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;tetrahydrate Chemical compound O.O.O.O.C=1C=CC=CC=1CNCCNCC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 WIDKTXGNSOORHA-CJHXQPGBSA-N 0.000 description 1
- 229960003808 nadifloxacin Drugs 0.000 description 1
- JYJTVFIEFKZWCJ-UHFFFAOYSA-N nadifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)CCC3=C1N1CCC(O)CC1 JYJTVFIEFKZWCJ-UHFFFAOYSA-N 0.000 description 1
- OIXVKQDWLFHVGR-WQDIDPJDSA-N neomycin B sulfate Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO OIXVKQDWLFHVGR-WQDIDPJDSA-N 0.000 description 1
- 229940053050 neomycin sulfate Drugs 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 229940037380 pivmecillinam hydrochloride Drugs 0.000 description 1
- UHPXMYLONAGUPC-WKLLBTDKSA-N pivmecillinam hydrochloride Chemical compound [H+].[Cl-].N([C@H]1[C@@H]2N(C1=O)[C@H](C(S2)(C)C)C(=O)OCOC(=O)C(C)(C)C)=CN1CCCCCC1 UHPXMYLONAGUPC-WKLLBTDKSA-N 0.000 description 1
- 229950009297 pivoxil Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229960003548 polymyxin b sulfate Drugs 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000013441 quality evaluation Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229960003485 ribostamycin Drugs 0.000 description 1
- NSKGQURZWSPSBC-NLZFXWNVSA-N ribostamycin Chemical compound N[C@H]1[C@H](O)[C@@H](O)[C@H](CN)O[C@@H]1O[C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](CO)O2)O)[C@H](O)[C@@H](N)C[C@H]1N NSKGQURZWSPSBC-NLZFXWNVSA-N 0.000 description 1
- 229940069575 rompun Drugs 0.000 description 1
- 229960003600 silver sulfadiazine Drugs 0.000 description 1
- HJHVQCXHVMGZNC-JCJNLNMISA-M sodium;(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoate Chemical compound [Na+].O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C([O-])=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C HJHVQCXHVMGZNC-JCJNLNMISA-M 0.000 description 1
- HLFCZZKCHVSOAP-WXIWBVQFSA-M sodium;(5e)-5-(carbamoylhydrazinylidene)-1-methyl-6-oxo-2,3-dihydroindole-2-sulfonate Chemical compound [Na+].NC(=O)N\N=C/1C(=O)C=C2N(C)C(S([O-])(=O)=O)CC2=C\1 HLFCZZKCHVSOAP-WXIWBVQFSA-M 0.000 description 1
- KKVTYAVXTDIPAP-UHFFFAOYSA-M sodium;methanesulfonate Chemical compound [Na+].CS([O-])(=O)=O KKVTYAVXTDIPAP-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000000551 statistical hypothesis test Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 description 1
- 229960005256 sulbactam Drugs 0.000 description 1
- 229960005158 sulfamethizole Drugs 0.000 description 1
- VACCAVUAMIDAGB-UHFFFAOYSA-N sulfamethizole Chemical compound S1C(C)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 VACCAVUAMIDAGB-UHFFFAOYSA-N 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- YZMCKZRAOLZXAZ-UHFFFAOYSA-N sulfisomidine Chemical compound CC1=NC(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 YZMCKZRAOLZXAZ-UHFFFAOYSA-N 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- OPYGFNJSCUDTBT-PMLPCWDUSA-N sultamicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(=O)OCOC(=O)[C@H]2C(S(=O)(=O)[C@H]3N2C(C3)=O)(C)C)(C)C)=CC=CC=C1 OPYGFNJSCUDTBT-PMLPCWDUSA-N 0.000 description 1
- 229960001636 sultamicillin tosylate Drugs 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 229960002780 talampicillin Drugs 0.000 description 1
- SOROUYSPFADXSN-SUWVAFIASA-N talampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(=O)OC2C3=CC=CC=C3C(=O)O2)(C)C)=CC=CC=C1 SOROUYSPFADXSN-SUWVAFIASA-N 0.000 description 1
- 229960001608 teicoplanin Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002076 thermal analysis method Methods 0.000 description 1
- 229960004659 ticarcillin Drugs 0.000 description 1
- ZBBCUBMBMZNEME-QBGWIPKPSA-L ticarcillin disodium Chemical compound [Na+].[Na+].C=1([C@@H](C([O-])=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)C=CSC=1 ZBBCUBMBMZNEME-QBGWIPKPSA-L 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- 229960001572 vancomycin hydrochloride Drugs 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/225—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00987—Apparatus or processes for manufacturing non-adhesive dressings or bandages
-
- A61F13/01012—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
- A61L15/325—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0029—Radiation
- A61L2/0035—Gamma radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0029—Radiation
- A61L2/007—Particle radiation, e.g. electron-beam, alpha or beta radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00365—Plasters use
- A61F2013/00463—Plasters use haemostatic
Abstract
本发明涉及一种止血及伤口治愈用创伤敷料及其制备方法。更具体地,本发明涉及一种创伤敷料的制备方法,该制备方法在制备创伤敷料时,通过调节透明质酸及胶原蛋白的配合比及冻结干燥条件,能够制备出不仅有最佳的创伤治愈促进效果及防止粘连效果,还具有优异的经济性及商业性的创伤敷料。
Description
技术领域
本发明涉及一种止血、防止粘连及伤口治愈用创伤敷料及其制备方法。更具体地说,本发明涉及一种创伤敷料的制备方法,该制备方法在制备创伤敷料时,通过调节透明质酸(hyaluronic acid,HA)及胶原蛋白的配合比及冻结干燥条件,能够制备出不仅有最佳的创伤治愈促进效果及防止粘连效果,还具有优异的经济性及商业性的创伤敷料。
背景技术
创伤(wound)是指组织的连续性被外部压力破坏的状态。创伤的治愈过程一般分为炎症步骤、增殖步骤及成熟步骤等三个步骤,为治疗创伤,需使用理想的敷料(dresssing)来阻止创伤部位暴露于外部环境,从而预防感染,抑制炎症反应。作为用于创伤治疗的生物敷料材料,正在开发许多以真皮中的胶原蛋白、弹性蛋白等物质为原料的敷料材料,这些物质相当于人体皮肤的组成部分。就胶原蛋白而言,它作为构成人体骨骼和皮肤等组织的主要蛋白质发挥着重要作用,皮肤的70%由胶原蛋白组成,其在组织重构(remodeling)和创伤治愈中起着重要的生理作用。此外,各项研究表明,胶原蛋白可有效治愈创伤。作为这些生物敷料材料的例子,韩国专利申请公开号第10-2010-0009305号公开了通过将疏水性脂肪酸基团与壳聚糖结合而增加细胞粘附蛋白的粘附性能的壳聚糖海绵及使用其的创伤敷料材料。
此外,透明质酸是由N-乙酰-D-氨基葡萄糖(N-acetyl-D-Glucosamine)和D-葡萄糖醛酸(D-glucuronic acid)组成,且上述重复单元呈线形连接的生物高分子物质,多存在于眼球的玻璃液、关节的滑液及鸡冠中。透明质酸因其优异的生物相容性和粘弹性被开发并用于各种用途,如术后防粘连剂、皱纹改善剂、整形辅助材料、关节功能改善剂、药物递送(drug delivery)载体及细胞培养支架(Scaffold)等(F.Manna,M.Dentini,P.Desider,O.De Pita,E.Mortilla,B.Maras,Journal of European Academy of Dermatology andVenereology,13(1999)183-192)。
而关于使用胶原蛋白和透明质酸的创伤敷料,韩国公开专利第2013-0009651号公开了一种软骨细胞治疗剂,其包含胶原蛋白、透明质酸衍生物及源自哺乳动物脐带的干细胞,但它是只单纯混合胶原蛋白和透明质酸的方式,存在不使用化学交联物质就无法为达到其目的剂型化的问题。此外,还存在可以使用的剂型只能为干燥相剂型的缺点,因此具有在使用领域及使用方法方面无法提供多种方法的局限性。
发明内容
发明要解决的问题
对此,本发明的发明人为开发能够大幅度提高创伤敷料的质量和可靠性的产品而进行了努力,结果发现了通过调节透明质酸钠及胶原蛋白的配合比及冻结干燥条件,不仅可以具有最佳的创伤治愈促进效果及防止粘连效果,还可具有优异的经济性及商业性,从而完成了本发明。
用于解决问题的手段
本发明的目的是提供止血及伤口治愈用创伤敷料的制备方法。
本发明的目的是提供一种创伤敷料的制备方法,所述制备方法包括以下步骤:
(A)混合含有0.4至1重量百分比的透明质酸或其盐、0.1至0.5重量百分比的胶原蛋白、及0.3至0.6重量百分比的氯化钠的水溶液的步骤;
(B)将所述水溶液的pH调节至6至8的步骤;
(C)对所述水溶液进行冻结干燥,使其变成片状的步骤;
(D)使所述冻结干燥的片保持不变或通过压缩调节厚度的步骤;以及
(D)对已完成所述冻结干燥及厚度调节的片进行环氧乙烷气体、伽马射线或电子束灭菌的步骤。
发明的效果
根据本发明的创伤敷料可以表现出最佳的创伤治愈促进效果及防止粘连效果。
附图说明
图1显示根据本发明的创伤敷料的体外止血效果测试的结果。
图2显示根据本发明的创伤敷料的利用大鼠的体内止血效果测试过程。
图3显示根据本发明的创伤敷料的利用大鼠的体内3分钟止血成功率。
图4显示根据本发明的创伤敷料的利用大鼠的体内止血效果测试中的总出血时间。
图5显示根据本发明的创伤敷料的防止粘连效果。
图6显示根据本发明的创伤敷料的防止粘连效果的组织病理学观察结果。
图7显示根据本发明的创伤敷料的产品质量评价结果。
具体实施方式
本发明的目的是提供止血及伤口治愈用创伤敷料的制备方法。
本说明书中所使用的术语“透明质酸”作为将透明质酸本身和透明质酸盐都包括在内的含义来使用。因此,以下使用的术语“透明质酸水溶液”是将透明质酸水溶液、透明质酸盐水溶液、及透明质酸和透明质酸盐的混合水溶液都包括在内的概念。所述透明质酸盐包括透明质酸钠、透明质酸钾、透明质酸钙、透明质酸镁、透明质酸锌、透明质酸钴等无机盐;以及透明质酸四丁基铵(Tetrabuty lammonium)等有机盐。根据情况,它们中的两种或更多种可以组合使用。
本发明的目的是提供一种创伤敷料的制备方法,所述创伤敷料包括以下步骤:
(A)混合含有0.4至1重量百分比的透明质酸或其盐、0.1至0.5重量百分比的胶原蛋白、及0.3至0.6重量百分比的氯化钠的水溶液的步骤;
(B)将所述水溶液的pH调节至6至8的步骤;
(C)对所述水溶液进行冻结干燥,使其变成片(pad)状的步骤;
(D)使所述冻结干燥的片保持不变或通过压缩调节厚度的步骤;以及
(D)对已完成所述冻结干燥及厚度调节的片进行环氧乙烷气体气体(EO gas)、伽马射线或电子束灭菌的步骤。
根据本发明的创伤敷料,其特征在于,所述创伤敷料为药物组合物或医药部外品组合物。
根据本发明的创伤敷料,其特征在于,所述水溶液为去离子水(deionized water,DW)、纯净水、注射用水或磷酸盐缓冲液(PBS)。
根据本发明的创伤敷料,其特征在于,所述透明质酸或其盐的分子量为50万至1000万道尔顿。
根据本发明的创伤敷料,其特征在于,所述胶原蛋白是从猪、羊、牛或鱼中提取的。
根据本发明的创伤敷料,其特征在于,所述步骤(A)中的混合是以100至300rpm的搅拌速度搅拌18至48小时。
根据本发明的创伤敷料,其特征在于,所述冻结干燥包括以下步骤:
(a)以如下条件进行冻结的步骤,即以60分钟达到5℃、在5℃条件冻结120分钟、以600分钟达到-5℃、在-5℃条件冻结60分钟、以及以600分钟达到-35℃;以及
(b)以如下条件进行干燥的步骤,即在-35℃及200mtorr真空度条件下干燥60分钟、在-35℃及150mtorr真空度条件下干燥60分钟、在100mtorr以下的真空度条件下以1440分钟达到-5℃、在100mtorr以下的真空度条件及-5℃条件下干燥1440分钟、在100mtorr以下的真空度条件下以600分钟达到20℃、在100mtorr以下的真空度条件及20℃条件下干燥720分钟。
根据本发明的创伤敷料,其特征在于,对所述创伤敷料按照环氧乙烷气体(EOgas)残留量试验方法进行试验时,具有小于25mg/kg的环氧乙烷(ETO)残留量以及小于25mg/kg的2-氯乙醇(ECH)残留量。
根据本发明的创伤敷料,其特征在于,对所述创伤敷料按照吸收能力试验方法进行试验时,具有500%至2000%的吸收能力。
根据本发明的创伤敷料,其特征在于,对所述创伤敷料按照干燥失重试验方法进行试验时,具有20%以下的干燥失重。
根据本发明的创伤敷料,其特征在于,对所述创伤敷料按照溶出物试验中pH试验方法进行试验时,具有1.5以下的pH差值。
根据本发明的创伤敷料,其特征在于,所述创伤敷料按照热分析试验方法进行试验时,在50℃以下的温度下不出现吸热峰或发热峰。
根据本发明的创伤敷料,其特征在于,所述创伤敷料的横向、纵向及厚度的尺寸分别为0.5cm至20cm、0.5cm至20cm、及0.01cm至1cm。
根据本发明的创伤敷料,其特征在于,所述创伤敷料每平方厘米含有1.06mg至5.75mg的透明质酸及0.45mg至6.03mg的胶原蛋白。
根据本发明的创伤敷料,其特征在于,所述创伤敷料还可以额外包括由杀菌消毒剂、止血剂、阿片类(Opioid)镇痛剂、磺胺类药物及抗生素组成的组选择的1种以上的药物。例如,所述杀菌消毒剂包括利凡诺(acrinol)、苯扎氯铵(Benzalkonium chloride)、苄索氯铵(Benzethonium chloride)、葡萄糖酸氯己定(Chlorhexidine Gluconate)、碘(Iodine)、碘酊(Iodine tincture)、碘仿(iodoform)或聚维酮碘(Povidone-iodine)。所述止血剂可以包括凝血酶(Thrombin)、海藻酸钠(Sodium Alginate)、ε-氨基己酸(ε-Aminocaproicacid)、油酸单乙醇胺(Monoethanolamine oleate)、卡络磺钠(Carbazochrome sodiumsulfonate)或氨甲环酸(Tranexamic acid)。所述阿片类镇痛剂可以包括盐酸吗啡(morphine HCl)或硫酸吗啡(Morphine sulfate)。所述磺胺类药物可以包括柳氮磺胺吡啶(Salazosulfapyridine)、磺胺嘧啶(Sulfadiazine)、磺胺嘧啶银(Silver sulfadiazine)、磺胺二甲氧嗪(Sulfadimethoxine)、磺胺甲噻二唑(Sulfamethizole)、磺胺甲恶唑(Sulfamethoxazole)、磺胺间甲氧嘧啶(sulfamonomethoxine)、磺胺二甲基异嘧啶(sulfisomidine)或磺胺二甲异嘧啶钠(sulfisomidine Sodium)。所述抗生素可以包括盐酸万古霉素(Vancomycin HCl)、盐酸林可霉素(Lincomycin HCl)、克林霉素(clindamycin)、替考拉宁(Teicoplanin)、苯氧乙基青霉素钾(phenethicillinpotassium)、青霉素钾(Benzylpenicillin Potassium)、苄星青霉素(Benzathinebenzylpenicillin)、莫匹罗星钙(二水合物)(Mupirocin Calcium Hydrate)、阿贝卡星硫酸盐(Arbekacin sulfate)、氨曲南(Aztreonam)、盐酸大观霉素(SpectinomycinHydrochloride)、盐酸匹美西林(Pivmecillinam Hydrochloride)、卡鲁莫南钠(CarumonamSodium)、粘杆菌素甲基磺酸钠(Colistin sodium methanesulfonate)、头孢磺啶钠(cefsulodin sodium)、头孢布烯(ceftibuten)、妥布霉素(Tobramycin)、硫酸阿米卡星(Amikacin Sulfate)、硫酸异帕米星(Isepamicin Sulfate)、硫酸卡那霉素(kanamycinsulfate)、硫酸新霉素(fradiomycin sulfate)、硫酸多粘菌素B(polymyxin B sulfate)、阿扑西林(Aspoxicillin)、阿莫西林(Amoxicillin)、氨苄西林(Ampicillin)、氨苄西林钠(Ampicillin Sodium)、盐酸头孢他美酯(Cefetamet pivoxil Hydrochloride)、盐酸头孢吡肟(Cefepime Hydrochloride)、盐酸头孢唑兰(Cefozopran Hydrochloride)、盐酸头孢替安(Cefotiam Hydrochloride)、盐酸头孢替安酯(Cefotiam Hexetil Hydrochloride)、盐酸头孢卡品酯(Cefcapene pivoxil hydrochloride)、盐酸头孢甲肟(CefmenoximeHydrochloride)、盐酸酞氨西林(Talampicillin hydrochloride)、盐酸巴坎西林(Bacampicillin Hydrochloride)、盐酸仑氨西林(lenampicillin Hydrochloride)、环己西林(Ciclacillin)、磺苄西林钠(Sulbenicillin Sodium)、头孢克洛(cefaclor)、头孢唑啉钠(cefazolin sodium)、头孢曲嗪丙二醇(Cefatrizine propylene glycol)、头孢羟氨苄(Cefadroxil)、头孢匹林钠(Cephapirin Sodium)、头孢孟多钠(cefamandole sodium)、头孢氨苄(Cefalexin)、头孢噻吩钠(Cephalothin Sodium)、头孢噻啶(Cefaloridine)、头孢克肟(Cefixime)、头孢西丁钠(Cefoxitine Sodium)、头孢他啶钠(CeftazidimeSodium)、头孢噻肟钠(Cefotaxime Sodium)、头孢替坦钠(Cefotetan Sodium)、头孢哌酮钠(Cefoperazone Sodium)、头孢妥仑匹酯(Cefditoren Pivoxil)、头孢地尼(cefdinir)、头孢他啶(Ceftazidime)、头孢唑肟钠(Ceftizoxime Sodium)、头孢替唑钠(Ceftezolesodium)、头孢特仑新戊酯(Cefteram pivoxil)、头孢曲松钠(ceftriaxone sodium)、头孢匹胺钠(Cefpiramide Sodium)、头孢拉宗钠(Cefbuperazone Sodium)、头孢泊肟酯(Cefpodoxime Proxetil)、头孢米诺钠(Cefminox Sodium)、头孢美唑钠(CefmetazoleSodium)、头孢拉定(Cefradine)、头孢沙定(Cefroxadine)、头孢呋辛酯(CefuroximeAxetil)、头孢呋辛钠(Cefuroxime Sodium)、替卡西林钠(Ticarcillin Sodium)、托西酸舒他西林(sultamicillin tosylate)、哌拉西林钠(piperacillin sodium)、法罗培南钠(Faropenem Sodium)、氟氧头孢钠(Flomoxef Sodium)、磷霉素(Fosfomycin)、美洛培南三水合物(Meropenem Trihydrate)、拉氧头孢钠(Latamoxef Sodium)、硫酸阿司米星(Astromicin Sulfate)、硫酸庆大霉素(Gentamicin Sulfate)、硫酸西索米星(SisomicinSulfate)、地贝卡星硫酸盐(Dibekacin Sulfate)、硫酸头孢噻利(cefoselis Sulfate)、硫酸头孢匹罗(Cefpirome Sulfate)、硫酸奈替米星(Netilmicin Sulfate)、卡那霉素B硫酸盐(Bekanamycin Sulfate)、硫酸小诺霉素(Micronomicin Sulfate)、硫酸核糖霉素(Ribostamycin Sulfate)、乙酰吉他霉素(Acetylkitasamycin)、乙酰螺旋霉素(Acetylspiramycin)、琥乙红霉素(Erythromycin ethyl succinate)、红霉素(Erythromycin)、依托红霉素(Erythromycin estolate)、吉他霉素(Kitasamycin)、克拉霉素(Clarithromycin)、乙酰麦迪霉素(Midecamycin Acetate)、酒石酸吉他霉素(Kitasamycin Tartrate)、交沙霉素(Josamycin)、硬脂酸红霉素(Erythromycinstearate)、丙酸交沙霉素(Josamycin propionate)、麦迪霉素(Midecamycin)、乳糖酸红霉素(Erythromycin Lactobionate)、罗红霉素(Roxithromycin)、罗他霉素(Rokitamycin)、盐酸四环素(Tetracycline Hydrochloride)、盐酸去甲金霉素(Demethylchlortetracycline Hydrochloride)、盐酸多西环素(Doxycycline Hyclate)、盐酸米诺环素(Minocycline Hydrochloride)、氯霉素(Chloramphenicol)、琥珀酸钠氯霉素(Chloramphenicol Sodium Succinate)、氯霉素棕榈酸酯(Chloramphenicolpalmitate)、环丝氨酸(Cycloserine)、利福平(Rifampicin)、硫酸恩维霉素(EnviomycinSulfate)、硫酸链霉素(Streptomycin Sulfate)、氧四环素盐酸盐(OxytetracyclineHydrochloride)、盐酸短杆菌肽S(Gramicidin S Hydrochloride)、四环素(Tetracycline)、那氟沙星(Nadifloxacin)、杆菌肽(Bacitracin)、夫西地酸钠(FusidateSodium)或硫酸粘杆菌素(Colistin sulfate)。
【具体实施例】
下面,将呈现多种实施例以帮助理解本发明。这些实施例仅为便于理解本发明而提供,本发明的范围不局限于这些实施例。
<实施例>
实施例1:按照透明质酸(HA)、胶原蛋白及氯化钠的配合比制备创伤敷料
将透明质酸钠、缺端胶原(Atelo collagen)(猪I型胶原蛋白,porcine typeⅠcollagen)及氯化钠按下表1所示的配合比搅拌制成水溶液,将各水溶液以13.5g±2%的比例分装在5×5cm的模具中。然后,根据表4中所述的步骤进行冻结干燥,并评价所生成的创伤敷料的质地。
【表1】
【表2】
结果发现,方法1的创伤敷料具有容易因物理刺激而受损的质感,方法8的创伤敷料质地较硬,难以变形为所需要的形状,因此很难实现商品化。相反,方法2至7的创伤敷料具有与现有的市售创伤敷料相似的柔软质感,易于商品化。
实施例2:根据不HA、胶原蛋白及氯化钠的配合比评价创伤敷料的止血效果(体外
(in
vitro))
对于根据上述实施例1至3的创伤敷料,根据以下实验方法进行了体外止血效果评价。
1)实验方法
①试液的制备
柠檬酸葡萄糖(Acid citrate dextrose):20mM的柠檬酸(citric acid)、110mM的柠檬酸钠(sodium citrate)及5mM的D-葡萄糖(D-glucose)溶于三蒸水(3DW)
200mM的CaCl2:200mM的CaCl2
②抗凝血(anti-coagulated blood)(柠檬酸化全血,citrated whole blood)的制备
从实验用兔子的动脉中抽取血液。以9:1(v/v)的比例将抽取的血液和酸式柠檬酸葡萄糖(Acid citrated dextrose)进行稀释,以抑制血液凝固。
③实验过程
将每个样本切成1.0×1.0cm(横×纵)的大小,放入聚丙烯管(polypropylenetube)(50ml的锥形离心管)中,在37℃下放置10分钟。除空白试验外,每支试管中加入0.2ml的200mMCaCl2,充分混合,并在37℃下放置5分钟。向每支试管加入25ml的蒸馏水,使未凝固的红细胞溶血。每种实验物质重复进行四次试验,并使用以下公式进行分析。
*凝血指数(Blood Clotting Index,BCI,%)=实验组的吸光度÷空白试液的平均吸光度×100
④统计分析
试验结果服从正态分布时,通过单因素方差分析(One-way ANOVA)中的Tukey法确认统计学显著性。
2)实验结果
凝血指数越低,评价为止血效果越好,结果见下表3。
【表3】
其结果,与阴性对照组相比,确认了根据方法1至8的创伤敷料及其他公司的产品的凝血指数显著偏低,而且与其他公司的产品相比,除方法6以外的所有方法1至5、7及8的创伤敷料的凝血指数均显著偏低(图1)。
实施例3:按照HA、胶原蛋白及氯化钠的配合比评价创伤敷料的止血效果(体内(in
vivo))
对于根据所述实施例1的创伤敷料进行如下实验:使大鼠肝脏诱发出血,并适用方法1、2及7的创伤敷料和其他公司的产品来评价止血效果。
1)实验方法
①试验物质:阴性对照组(纱布)、根据方法1、2及7的创伤敷料、其他公司的产品
②麻醉:肌肉注射舒泰(zoletil)(30mg/kg)、龙朋(rompun)(20mg/kg),保持麻醉后进行实验。
③适用方法:露出肝左叶,用3mm的活检穿孔器(biopsy punch)切出3~4mm深的伤口,以圆柱状将相应部位切除来诱导出血。将各实验物质切成2×2cm,并适用于出血部位(图2)。
④评价方法
止血时间:粘贴试验物质后,每隔3、5、6、9分钟确认是否止血,确认各实验组的3分钟止血成功率。
⑤检验统计显著性
结果值服从正态分布时,通过单因素方差分析中的Tukey法确认统计学显著性。
2)结果
针对阴性对照组、方法1、2及7的创伤敷料及其他公司的产品确认了3分钟止血成功率,其结果分别显示出0%、40%、60%、70%及20%的3分钟止血成功率(图3)。此外,确认总出血时间的结果,阴性对照组、根据方法1、2及7的创伤敷料及其他公司产品分别为7.8分钟、4.2分钟、3.8分钟、3.8分钟及6分钟,尤其是根据方法2及7的创伤敷料与其他公司的产品相比,总出血时间在统计学上显著变短(图4)。
实施例4:按照HA、胶原蛋白及氯化钠的配合比的创伤敷料的防止粘连评价
对于根据所述实施例1的创伤敷料,适用于大鼠的腹腔内来评价了防止粘连性能。
1)实验方法
①试验物质:阴性对照组(纱布)、根据实施例1的创伤敷料中的方法2的创伤敷料、其他公司的产品
②麻醉:肌肉注射舒泰(30mg/kg)、龙朋(10mg/kg),保持麻醉后进行实验。
③适用方法:在盲肠和腹壁的缺损部位的结扎诱导之前,将实验物质在无菌状态下切成1.5×1.5cm,适用于诱导粘连的组织之间。
④评价方法
使用二氧化碳室对大鼠实施安乐死,确认适用于腹腔内的实验物质,肉眼评价了诱发粘连的部位。如下表,将粘连程度进行分数化,并计算各组的平均值。
【表4】
⑤统计显著性检验结果值服从正态分布时,通过单因素方差分析中的tukey法确认统计学显著性。
⑥组织病理学观察
采集包括粘连诱发部位及正常组织在内的组织样本,采集的组织用10%的福尔马林固定后,经过修整,利用组织预处理器在酒精中脱水,进行预处理,以使石蜡更容易渗透。利用包埋机,在包埋盒中利用石蜡将其固定,制备组织块,用微型切割机进行切割并修整。制备组织片,用染色机进行HE(Haematoxylin&Eosin)染色,并在显微镜下观察。
2)结果
①组织粘连评价
根据本发明的方法2的创伤治疗剂的情况下,表现出20%的粘连率,确认了其与阴性对照组的87%及市售产品的40%相比,具有明显改善的防止粘连效果(图5)。
【表5】
②组织病理学观察评价
对于阴性对照组而言,大部分由于肉芽组织(Granulation tissue)的形成,腹膜和盲肠之间发生了粘连,但是根据本发明的方法2的创伤治疗剂,未观察到肉芽组织,并确认无粘连痕迹(图6)。
实施例5:根据冻结干燥条件的产品性能评价
综合考虑根据实施例1至3的创伤敷料的经济性、质感及止血效果的结果,最终选择了方法2的创伤敷料,并评价了根据下表6所示的冻结干燥条件的产品状态。
【表6】
根据其结果,确认了在1号(NO.1)的条件下进行冻结干燥时,冻结干燥的收率小于50%,冻结干燥进行期间的冻结不良(裂纹(crack))大于50%,在2号(No.2)的条件下进行冻结干燥时,冻结干燥的收率小于70%,冻结干燥进行期间的冻结不良(裂纹)大于30%。另一方面,在3号(No.3)的条件下进行冻结干燥时,冻结干燥的收率大于90%,冻结干燥进行期间的冻结不良(裂纹)小于10%(图7)。
实施例6:评价根据方法2的创伤敷料的特性
5-1.评价根据实施例1制备的方法2的创伤敷料中的ETO及ECH残留量,其结果发现方法2的创伤敷料具有小于25mg/kg的ETO残留量及小于25mg/kg的ECH残留量。
【表7】
5-2.评价根据实施例1制备的方法2的创伤敷料的吸收能力,结果发现其具有约670%的吸收能力。
【表8】
检测项目 | 单位 | 结果值 |
吸收能力 | % | 672.5 |
以上对本发明的特定部分进行了详细描述,对于本领域的普通技术人员而言,这些具体技术仅是优选的实施例,并非对本发明范围的限制。因此,本发明的实质范围应由所附权利要求及其等同物来定义。
Claims (8)
1.一种创伤敷料的制备方法,其特征在于,包括:
(A)混合含有0.4至1重量百分比的透明质酸或其盐、0.1至0.5重量百分比的胶原蛋白、及0.3至0.6重量百分比的氯化钠的水溶液的步骤;
(B)将所述水溶液的pH调节至6至8的步骤;
(C)对所述水溶液进行冻结干燥,使其变成片状的步骤;
(D)使所述冻结干燥的片保持不变或通过压缩来调节厚度的步骤;以及
(E)对已完成所述冻结干燥及厚度调节的片进行环氧乙烷气体灭菌、伽马射线灭菌或电子束灭菌的步骤,
其中,所述冻结干燥包括:
(a)以如下条件进行冻结的步骤,即以60分钟达到5℃、在5℃条件冻结120分钟、以600分钟达到-5℃、在-5℃条件冻结60分钟、以600分钟达到-35℃;以及
(b)以如下条件进行干燥的步骤,即在-35℃及200mtorr真空度条件下干燥60分钟、在-35℃及150mtorr真空度条件下干燥60分钟、在100mtorr以下的真空度条件下以1440分钟达到-5℃、在100mtorr以下的真空度条件及-5℃条件下干燥1440分钟、在100mtorr以下的真空度条件下以600分钟达到20℃、在100mtorr以下的真空度条件及20℃条件下干燥720分钟。
2.根据权利要求1所述的创伤敷料的制备方法,其特征在于,所述创伤敷料为药物组合物或医药部外品组合物。
3.根据权利要求1所述的创伤敷料的制备方法,其特征在于,所述透明质酸或其盐的分子量为50万至1000万道尔顿。
4.根据权利要求1所述的创伤敷料的制备方法,其特征在于,所述胶原蛋白从猪、羊、牛或鱼中提取。
5.根据权利要求1所述的创伤敷料的制备方法,其特征在于,所述步骤(A)中的混合是以100至300rpm的搅拌速度搅拌18至48小时。
6.根据权利要求1所述的创伤敷料的制备方法,其特征在于,按照吸收能力的试验方法进行试验时,所述创伤敷料具有500%至2000%吸收能力。
7.根据权利要求1所述的创伤敷料的制备方法,其特征在于,所述创伤敷料的横向、纵向及厚度的尺寸分别为0.5cm至20cm、0.5cm至20cm、及0.01cm至1cm。
8.根据权利要求1所述的创伤敷料的制备方法,其特征在于,所述创伤敷料每平方厘米含有1.06mg至5.75mg的透明质酸及0.45mg至6.03mg的胶原蛋白。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190151554A KR102311547B1 (ko) | 2019-11-22 | 2019-11-22 | 지혈 및 상처치유용 창상피복재 및 이의 제조 방법 |
KR10-2019-0151554 | 2019-11-22 | ||
PCT/KR2020/016458 WO2021101311A1 (ko) | 2019-11-22 | 2020-11-20 | 지혈 및 상처치유용 창상피복재 및 이의 제조 방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114728093A CN114728093A (zh) | 2022-07-08 |
CN114728093B true CN114728093B (zh) | 2023-04-28 |
Family
ID=75981367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202080080438.9A Active CN114728093B (zh) | 2019-11-22 | 2020-11-20 | 止血及伤口治愈用创伤敷料及其制备方法 |
Country Status (3)
Country | Link |
---|---|
KR (1) | KR102311547B1 (zh) |
CN (1) | CN114728093B (zh) |
WO (1) | WO2021101311A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230017722A (ko) | 2021-07-28 | 2023-02-06 | 주식회사 타임바이오 | 제대혈간세포 유래 엑소좀을 포함하는 창상 치료 또는 창상 치료 촉진용 조성물 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101001649A (zh) * | 2004-07-09 | 2007-07-18 | 弗罗桑公司 | 包括透明质酸的止血组合物 |
CN101700409A (zh) * | 2009-11-20 | 2010-05-05 | 佘振定 | 一种由纯天然材料制备的创伤用材料 |
KR20130083596A (ko) * | 2012-01-13 | 2013-07-23 | 한림대학교 산학협력단 | 콜라겐 및 히알루론산을 함유하는 창상 치료용 진피 대체물의 제조방법 및 이로부터 제조된 진피 대체물 |
CN105705171A (zh) * | 2013-11-08 | 2016-06-22 | 世元世龙技术株式会社 | 通过胶原蛋白和玻尿酸的天然交联强化其橡胶性质物性的生体材料物质及其制造方法和使用方法 |
CN106068133A (zh) * | 2015-01-30 | 2016-11-02 | 株式会社Meditip | 使用生物聚合物的伤口敷料的制备方法、及利用其方法制备的使用生物聚合物的伤口敷料 |
KR20170060477A (ko) * | 2015-11-24 | 2017-06-01 | 한림대학교 산학협력단 | 고막재생용 콜라겐 패치의 제조방법 및 그 방법에 의해 제조된 고막재생용 콜라겐 패치 |
-
2019
- 2019-11-22 KR KR1020190151554A patent/KR102311547B1/ko active IP Right Grant
-
2020
- 2020-11-20 CN CN202080080438.9A patent/CN114728093B/zh active Active
- 2020-11-20 WO PCT/KR2020/016458 patent/WO2021101311A1/ko active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101001649A (zh) * | 2004-07-09 | 2007-07-18 | 弗罗桑公司 | 包括透明质酸的止血组合物 |
CN101700409A (zh) * | 2009-11-20 | 2010-05-05 | 佘振定 | 一种由纯天然材料制备的创伤用材料 |
KR20130083596A (ko) * | 2012-01-13 | 2013-07-23 | 한림대학교 산학협력단 | 콜라겐 및 히알루론산을 함유하는 창상 치료용 진피 대체물의 제조방법 및 이로부터 제조된 진피 대체물 |
CN105705171A (zh) * | 2013-11-08 | 2016-06-22 | 世元世龙技术株式会社 | 通过胶原蛋白和玻尿酸的天然交联强化其橡胶性质物性的生体材料物质及其制造方法和使用方法 |
CN106068133A (zh) * | 2015-01-30 | 2016-11-02 | 株式会社Meditip | 使用生物聚合物的伤口敷料的制备方法、及利用其方法制备的使用生物聚合物的伤口敷料 |
KR20170060477A (ko) * | 2015-11-24 | 2017-06-01 | 한림대학교 산학협력단 | 고막재생용 콜라겐 패치의 제조방법 및 그 방법에 의해 제조된 고막재생용 콜라겐 패치 |
Also Published As
Publication number | Publication date |
---|---|
KR102311547B1 (ko) | 2021-10-13 |
KR20210063076A (ko) | 2021-06-01 |
WO2021101311A1 (ko) | 2021-05-27 |
CN114728093A (zh) | 2022-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7013336B2 (ja) | インサイチュー架橋性ポリマー組成物およびその方法 | |
EP0048558B1 (en) | Treatment of osteitis | |
KR101330652B1 (ko) | 성장인자 담지 가능한 유착방지용 고분자 조성물 | |
US20180036338A1 (en) | Flowable hemostatic composition | |
NZ544403A (en) | Semi-synthetic platelet gel and method for the preparation thereof | |
JP5460580B2 (ja) | 癒合における新規活性成分及びその使用 | |
KR101452041B1 (ko) | 유착방지재 및 유착방지 방법 | |
CN105377319B (zh) | 用于药物释放的化合物和组合物 | |
EP3060266A1 (en) | Chitosan paste wound dressing | |
AU2014340012A1 (en) | Chitosan paste wound dressing | |
AU2013298102B2 (en) | Compositions and methods for the treatment of bone voids and open fractures | |
CN114728093B (zh) | 止血及伤口治愈用创伤敷料及其制备方法 | |
WO2003084571A1 (fr) | Composition therapeutique destinee aux maladies infectieuses des os | |
JP6916353B1 (ja) | 癒着防止用高分子組成物 | |
KR20160127672A (ko) | 생체적합성 천연고분자 및 dna 단편 혼합물을 함유하는 유착방지제 및 이의 제조 방법 | |
KR20130142272A (ko) | 생체 적합성 고분자를 이용한 이식용 재료의 제조방법 | |
KR101845885B1 (ko) | 입자형 무세포 진피 기반의 온도감응성 유착방지 조성물의 제조방법 | |
CN109847111B (zh) | 一种包含白及多糖的防粘连材料及其制备方法 | |
CZ20032011A3 (cs) | Použití nemetabolizovatelného cukru a polymerového absorpčního činidla pro podporu buněčné rekonstrukce a/nebo buněčné diferenciace | |
Shahzadi et al. | Application of Natural Polymers in Wound Dressings | |
EP2740500A2 (en) | Composition for use in the prophylaxis of post-surgical adhesions | |
CN117430938A (zh) | 水凝胶材料、水凝胶组合物及其制备方法和应用 | |
Witte | Hyaluronan and its application in equine lower limb wound healing | |
CZ16784U1 (cs) | Přípravek pro hojení ran a prevenci adheze bandáže na ránu obsahující polysacharidy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |